Allergan Posurdex NDA by year end?
This article was originally published in Pharmaceutical Approvals Monthly
Allergan plans to submit a macular edema NDA for Posurdex (dexamethasone) in late 2006 or early 2007, the company says May 3. The firm is highlighting less frequent dosing it says is possible with the extended-release drug delivery technology used in the proprietary dexamethasone formulation (1Pharmaceutical Approvals Monthly February 2006, p. 16). Allergan notes it also has completed preclinical studies of Posurdex in combination with anti-VEGF agents for treatment of macular degeneration. Genentech's VEGF agent Lucentis (ranibizumab) has a June 29 priority review user fee date for macular degeneration (2Pharmaceutical Approvals Monthly March 2006, In Brief)...
You may also be interested in...
Allergan and partner Sirna hope to advance novel RNAi-based retinal disease agent Sirna-027 into Phase II trials for macular degeneration this year, according to Allergan
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.